Loading clinical trials...
Loading clinical trials...
Development of a New Algorithm-based Classification for Glioma
ATRX (X-linked mental retardation and alpha-thalassaemia syndrome protein) loss and pTERT (Telomerase reverse transcriptase) mutation are diagnostic markers of gliomas. However, 4 to 28% of gliomas shows none of these alterations. The aim of this project is to propose a new test able to detect the telomeric status for every glioma. Based on this test and other markers (such as mutation of IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2)), investigators propose an algorithm, able to classify the main subtypes of gliomas (astrocytoma, oligodendroglioma and glioblastoma).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Institut de Pathologie Est, Biopathologie moléculaire, Hôpitaux Est, HCL
Bron, France
Start Date
December 1, 2018
Primary Completion Date
March 1, 2020
Completion Date
March 1, 2021
Last Updated
December 11, 2019
300
ACTUAL participants
PCR (Polymerase Chain Reaction)
OTHER
Lead Sponsor
Hospices Civils de Lyon
NCT06860594
NCT05099003
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05839379